Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Phase I/II Study of DFP-10917 in Relapsed/Refractory AML Demonstrates Efficacy and Safety Profile Suitable for Phase III Study

Hagop M. Kantarjian, MD, Elias J. Jabbour, MD, Guillermo Garcia-Manero, MD, Tapan M. Kadia, MD, Courtney D. DiNardo, MD MSCE, Naval G. Daver, MD, Gautam Borthakur, MD, Nitin Jain, MD, Jane Waukau, RN, BSN, Monica Kwari, RN, BSN, Barry Douglas Anderson, MD PhD, Kenzo Iizuka, Cheng Jin, MD PhD, Chun Zhang, MD, Farhad Ravandi, MD, William Plunkett, PhD

Blood (2016) 128 (22): 2822.

https://doi.org/10.1182/blood.V128.22.2822.2822

Published: 2016

Journal Articles

Results of a Phase I/II Study of DFP-10917, a Nucleoside Analog, Given By Continuous Infusion (CI) in Patients (pts) with Relapsed or Refractory Acute Leukemia

Hagop Kantarjian, MD, Elias Jabbour, MD, Guillermo Garcia-Manero, MD, Tapan Kadia, MD, Courtney DiNardo, MD, Naval Daver, MD, Gautam Borthakur, MD, Nitin Jain, MD, Jane Waukau, RN, BSN, Monica Kwari, RN, BSN, Barry Douglas Anderson, MD PhD, Kenzo Iizuka, Cheng Jin, MD PhD, William Plunkett, PhD

Blood (2015) 126 (23): 3804.

https://doi.org/10.1182/blood.V126.23.3804.3804

Published: 2015

Journal Articles

Oral Clofarabine in the Treatment of Patients with Higher-Risk Myelodysplastic Syndrome.

Stefan Faderl, MD, Guillermo Garcia-Manero, MD, Zeev Estrov, MD, Farhad Ravandi, MD, Gautam Borthakur, MD, Jorge Cortes, MD, Susan O'Brien, MD, Varsha Gandhi, PhD, William Plunkett, PhD, Anna L. Byrd, RN, Monica Kwari, RN, Hagop Kantarjian, MD

Blood (2009) 114 (22): 118.

https://doi.org/10.1182/blood.V114.22.118.118

Published: 2009

Journal Articles

Results of an Exploratory Study of Oral (po) and Intravenous (iv) Clofarabine in Patients with Myelodysplastic Syndrome.

Stefan Faderl, MD, Guillermo Garcia-Manero, MD, Varsha Gandhi, PhD, MS, BS, Farhad Ravandi, MD, Gautam Borthakur, MD, Deborah A. Thomas, MD, Alessandra Ferrajoli, MD, Zeev Estrov, MD, William Plunkett, PhD, BS, Anna Byrd, RN, Monica Kwari, RN, Hagop M. Kantarjian, MD

Blood (2007) 110 (11): 1455.

https://doi.org/10.1182/blood.V110.11.1455.1455

Published: 2007

Journal Articles

Intensification of Hyper-CVAD with L-Asparaginase, Vincristine, and Dexamethasone ("Augmented Hyper-CVAD") Has Activity in Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL).

Stefan Faderl, MD, Deborah A. Thomas, MD, Farhad Ravandi, MD, Guillermo Garcia-Manero, MD, Miloslav Beran, MD PhD, Michael Rytting, MD, Charles A. Koller, MD, Srdan Verstovsek, MD PhD, Gautam Borthakur, MD, Michael Andreeff, MD PhD, Steve Kornblau, MD, Susan O’Brien, MD, Khanh Vu, MD, Monica Kwari, RN, Jennie Bretz, RN, Hagop M. Kantarjian, MD

Blood (2007) 110 (11): 4324.

https://doi.org/10.1182/blood.V110.11.4324.4324

Published: 2007

Journal Articles

Phase I/II Study of Clofarabine Plus Cyclophosphamide in Adults with Relapsed and Refractory Acute Lymphoblastic Leukemia (ALL).

Stefan Faderl, MD, Deborah A. Thomas, MD, Varsha Gandhi, PhD MS BS, Gautam Borthakur, MD, Xuelin Huang, PhD, William Plunkett, PhD BS, Jan Burger, MD PhD, Jorge Cortes, MD, Susan O’Brien, MD, Farhad Ravandi, MD, Jennie Bretz, RN, Monica Kwari, RN, Hagop M. Kantarjian, MD

Blood (2007) 110 (11): 4335.

https://doi.org/10.1182/blood.V110.11.4335.4335

Published: 2007

Journal Articles

Clofarabine Plus Anthracycline Combinations in Acute Myeloid Leukemia (AML) Salvage.

Stefan Faderl, MD, Alessandra Ferrajoli, MD, Farhad Ravandi-Kashani, MD, Srdan Verstovsek, MD, PhD, William G. Wierda, MD, PhD, Gautam Borthakur, MD, Deborah Thomas, MD, Jorge Cortes, MD, Steven M. Kornblau, MD, Zeev Estrov, MD, Michael Andreeff, MD, PhD, Miloslav Beran, MD, PhD, DVM, Francis Giles, MD, Xuelin Huang, PhD, Monica Kwari, RN, Hagop M. Kantarjian, MD

Blood (2006) 108 (11): 159.

https://doi.org/10.1182/blood.V108.11.159.159

Published: 2006

Journal Articles

Clofarabine Plus Cytarabine (ARA-C) Combination Is Active in Newly Diagnosed Patients (PTS) ≥ Age 50 with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS).

Stefan Faderl, MD, Varsha Gandhi, PhD, Srdan Verstovsek, MD, PhD, Jorge Cortes, MD, Farhad Ravandi-Kashani, MD, Miloslav Beran, MD, PhD, Guillermo Garcia-Manero, MD, Charles Koller, MD, Susan O’Brien, MD, Alessandra Ferrajoli, MD, Zeev Estrov, MD, Monica Kwari, RN, William Plunkett, PhD, Hagop M. Kantarjian, MD

Blood (2004) 104 (11): 875.

https://doi.org/10.1182/blood.V104.11.875.875

Published: 2004

Journal Articles

Phase I Study of Clofarabine Plus Idarubicin and Clofarabine Plus Idarubicin Plus Cytarabine (ARA-C) in Patients (PTS) with Relapsed and Primary Refractory Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Myeloid Blast Phase of Chronic Myeloid Leukemia (CML).

Stefan Faderl, MD, Alessandra Ferrajolil, MD, William Wierda, MD PhD, Srdan Verstovsek, MD, PhD, Farhad Ravandi-Kashani, MD, Guillermo Garcia-Manero, MD, Elihu Estey, MD, Deborah A. Thomas, MD, Steve Kornblau, MD, Monica Kwari, RN, Varsha Gandhi, PhD, Hagop M. Kantarjian, MD

Blood (2004) 104 (11): 1809.

https://doi.org/10.1182/blood.V104.11.1809.1809

Published: 2004

NARROW

Phase I/II Study of DFP-10917 in Relapsed/Refractory AML Demonstrates Efficacy and Safety Profile Suitable for Phase III Study

Results of a Phase I/II Study of DFP-10917, a Nucleoside Analog, Given By Continuous Infusion (CI) in Patients (pts) with Relapsed or Refractory Acute Leukemia

Oral Clofarabine in the Treatment of Patients with Higher-Risk Myelodysplastic Syndrome.

Results of an Exploratory Study of Oral (po) and Intravenous (iv) Clofarabine in Patients with Myelodysplastic Syndrome.

Intensification of Hyper-CVAD with L-Asparaginase, Vincristine, and Dexamethasone ("Augmented Hyper-CVAD") Has Activity in Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL).

Phase I/II Study of Clofarabine Plus Cyclophosphamide in Adults with Relapsed and Refractory Acute Lymphoblastic Leukemia (ALL).

Clofarabine Plus Anthracycline Combinations in Acute Myeloid Leukemia (AML) Salvage.

Clofarabine Plus Cytarabine (ARA-C) Combination Is Active in Newly Diagnosed Patients (PTS) ≥ Age 50 with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS).

Phase I Study of Clofarabine Plus Idarubicin and Clofarabine Plus Idarubicin Plus Cytarabine (ARA-C) in Patients (PTS) with Relapsed and Primary Refractory Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Myeloid Blast Phase of Chronic Myeloid Leukemia (CML).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only